Levocertizine 5 mg
Levocetrizine is third generation non-sedative antihistamine. It is derived from second generation cetirizine. It is levo form of cetirizine which belongs to second generation. It causes blocking of histamine receptors and prevents the binding of its receptors. In other words it prevents the release of allergic chemicals and decreased the supply of blood to that area.
- Hives (patches of red, swollen, itchy skin).
- Seasonal allergic rhinitis
- Perennial rhinitis
- Chronic idiopathic urticaria
- Adult dosage (ages 18–64 years)
The typical dosage is one 5-mg tablet once per day in the evening.
- Child dosage (ages 12–17 years)
The typical dosage is one 5-mg tablet once per day in the evening
- Child dosage (ages 6–11 years)
The typical dosage is one half-tablet (2.5 mg) once per day in the evening.
Mechanism of Action
It competes with histamine for binding at H1 receptor on the effectors cell surface which causes the suppression histaminic edema and pruritus. The low incidence of sedation is because the reduced penetration of cetrizine into CNS.
It is well absorbed in the body with mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours
It is well distributed in the body with 93% plasma protein binding. Vd is 0.41kg
The plasma half life is 7.9 ± 1.9 hours; total body clearance is 0.63 ml/min/kg
- Patients with hypersensitivity to such drugs
- Renal disease
- Pediatric patients with renal impairment
- Long treatment can cause somnolence, fatigue, and asthenia
- Patient should not involved in those task which require complete concentration
- Patients with predisposing factors of urinary retention
- Use in pregnant patients when clearly needed